<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3409">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355364</url>
  </required_header>
  <id_info>
    <org_study_id>CGE_2020_9</org_study_id>
    <nct_id>NCT04355364</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)</brief_title>
  <acronym>COVIDORNASE</acronym>
  <official_title>Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the effects of Dornase Alfa in COVID19 (coronavirus&#xD;
      disease of 2019) patients, the medical condition caused by the Severe Acute Respiratory&#xD;
      Syndrome Coronavirus 2 (SARS-CoV-2). Dornase Alfa is a FDA-approved drug for the treatment of&#xD;
      cystic fibrosis, which facilitates mucus clearance by cutting apart neutrophil-derived&#xD;
      extracellular double-stranded DNA. This study intends to define the impact of aerosolized&#xD;
      intra-tracheal Dornase Alfa administration on the severity and progression of acute&#xD;
      respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus&#xD;
      thinner and looser, promoting improved clearance of secretions and reduce extracellular&#xD;
      double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the&#xD;
      lungs.&#xD;
&#xD;
      The study will recruit mechanically ventilated patients hospitalized in ICU who have been&#xD;
      diagnosed with COVID-19 and meet ARDS criteria. It is a prospective, randomized, controlled,&#xD;
      multicentric, open-label clinical trial.&#xD;
&#xD;
      The goal is to recruit 100 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) is the most severe form of COVID-19 with a&#xD;
      mortality reaching 50%. To date, no specific therapy has been shown to be effective. During&#xD;
      an acute viral respiratory infection, lungs are the site of an intense neutrophil&#xD;
      recruitment. Recruited neutrophils generate NETs (extracellular neutrophil traps) in the&#xD;
      alveoli and bronchioles. NETs have been shown to be involved in bronchoalveolar congestion&#xD;
      and amplification of the inflammatory response during viral pneumonia responsible for ARDS.&#xD;
      Deoxyribonuclease 1 (DNAse 1) is an enzyme capable of cutting apart extracellular DNA&#xD;
      strands, the backbone of NETs. The administration of recombinant human DNAse 1 (dornase alfa)&#xD;
      leads to the loosening of the broncho-alveolar mucus and to a reduction in the inflammatory&#xD;
      response within the alveoli.&#xD;
&#xD;
      By conducting a randomized, open-label, multicenter, controlled trial, our goal is to&#xD;
      evaluate the efficacy and safety of aerosolized intra-tracheal dornase alfa administration in&#xD;
      mechanically ventilated patients hospitalized for COVID19-related ARDS.&#xD;
&#xD;
      This is a randomized, controlled, multicentric, open-label clinical trial to evaluate the&#xD;
      efficacy and safety of dornase alfa administration aerosol, intensive care hospitalized&#xD;
      patients with COVID19-related ARDS.&#xD;
&#xD;
      The comparison of D7-D0 between the groups will be carried out using a linear regression&#xD;
      fitted to the stratification factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">April 21, 2021</completion_date>
  <primary_completion_date type="Actual">November 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP &gt; 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure &lt; 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2&lt;150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure &lt; 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2&lt;150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of intratracheal administration: occurrence of at least one grade improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>The primary endpoint is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from severe to moderate or from moderate to mild</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP &gt; 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure &lt; 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2&lt;150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the usual care in accordance with good practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase Alfa Inhalation Solution [Pulmozyme]</intervention_name>
    <description>Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard procedure</intervention_name>
    <description>Patients will receive the usual care in accordance with good practice.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria&#xD;
&#xD;
          -  Adult patient (age ≥ 18 years old);&#xD;
&#xD;
          -  Hospitalized in intensive care ;&#xD;
&#xD;
          -  Severe COVID-19 pneumonia (positive diagnosis by RT-PCR or SARS-CoV-2 antigen test on&#xD;
             nasopharyngeal or deep respiratory specimen and/or evocative thoracic scan: frosted&#xD;
             glass opacities, consolidation, cross-linking, thickening of interlobular septa,&#xD;
             peripheral nodules) with ARDS criteria according to Berlin criteria (PaO2/FiO2 ≤ 300&#xD;
             and PEP ≥ 5).&#xD;
&#xD;
          -  With respiratory assistance (intubated or NIV or ONHD) for less than 8 days;&#xD;
&#xD;
          -  With an expected duration of respiratory assistance &gt; 48 hours;&#xD;
&#xD;
          -  Carrier of an arterial catheter ;&#xD;
&#xD;
          -  For which 4 PaO2/FiO2 values on arterial blood over the last 24 hours are available;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Dornase alfa or any of the excipients;&#xD;
&#xD;
          -  Pregnant or breastfeeding status;&#xD;
&#xD;
          -  Patient with legal protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Grégoire</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Fondation A de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe Désilles</last_name>
    <phone>0148037068</phone>
    <email>jpdesilles@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amélie Yavchitz</last_name>
    <phone>0148037068</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Fondation A. de Rotschhild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Yavchitz</last_name>
      <phone>0148036870</phone>
    </contact>
    <investigator>
      <last_name>Charles GREGOIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

